It addresses consultation;
neurotoxin preparation, instrumentation, and injection techniques for various problems; and fillers, including anesthesia techniques, injection methods, and techniques for different problems.
"We have discovered a
neurotoxin, PMP1, that selectively targets malaria mosquitos, demonstrating that this family of toxins have a much broader host spectrum than previously believed", said Pal Stenmark of Stockholm University and Lund University.
Merz, a Germany-based
neurotoxin company, has received European approval for its Xeomin (incobotulinumtoxinA) intended for the symptomatic treatment of chronic sialorrhea (drooling) due to neurological disorders in adult patients, it was reported yesterday.
"Evolus is well capitalized, our sales team is hired and trained, our head-to-head clinical data versus BOTOX(R) is published and we are now on the brink of launching the first new 900kDa
neurotoxin to enter the United States in nearly 30 years," said David Moatazedi, president and CEO.
He's regarded as such because he literally found a different purpose for the
neurotoxin, botulinum toxin which was originally used to correct Strabismus or cross eyedness back in the 90s.
Mouse bioassay (MBA) is the standard test for botulinum
neurotoxin detection.
Allergan has entered an agreement to acquire Bonti, Inc., a privately held clinical-stage biotechnology company focused on the development and commercialization of novel, fast-acting
neurotoxin programs for aesthetic and therapeutic applications, for an upfront payment of $195 million and additional potential commercial milestone payments.
18 September 2018 - Ireland-based pharmaceutical company Allergan plc (NYSE: AGN) has agreed to acquire California, US-based clinical-stage biotechnology firm Bonti, Inc., focussed on the development and commercialisation of novel, fast-acting
neurotoxin programmes for aesthetic and therapeutic applications, the company said..
Based in Newport Beach, CA, Bonti is a privately held clinical-stage biotechnology company focused on the development and commercialisation of novel, fast-acting
neurotoxin programmess for aesthetic and therapeutic applications.
"This is a unique discovery of a botulinum
neurotoxin in a bacterium that is both ubiquitous in animals and a serious problem in human health," says Lebreton.